Valuation : BioNTech SE

Market Cap 20.86B 24.19B 19.75B 17.89B 33.56B 2,312B 33.74B 235B 90.17B 1,175B 90.88B 88.86B 3,717B P/E 2026 *
-14.6x
P/E 2027 * -15.3x
Enterprise Value 9.5B 11.01B 8.99B 8.14B 15.27B 1,052B 15.36B 107B 41.04B 535B 41.36B 40.44B 1,692B EV / Sales 2026 *
5.26x
EV / Sales 2027 * 5.98x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 week-6.16%
Current month-4.87%
1 month+3.23%
3 months+10.74%
6 months+14.48%
Current year+2.09%
1 week 82.7
Extreme 82.7
90.25
1 month 78.4
Extreme 78.4
103.1
3 years 68.35
Extreme 68.35
124.7
5 years 68.35
Extreme 68.35
335.3
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 2017-12-31
Chief Executive Officer 61 2008-06-01
Director of Finance/CFO - 2025-06-30
Director TitleAgeSince
Chairman 56 2008-06-01
Director/Board Member 69 2008-06-01
Director/Board Member 65 2017-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+0.66%-6.16%-5.14%-25.93% 24.22B
-2.11%-3.44%+41.04%+98.48% 68.24B
-0.23%-6.42%+30.19%+76.15% 62.23B
+1.67%+2.16%-11.32%+392.80% 27.8B
-1.05%-7.30%+25.00%+12.31% 24.86B
+0.34%-5.98%-4.23%-19.48% 24.22B
+0.43%-4.78%+18.26%-20.61% 19.36B
-3.03%-5.19%+192.88%+340.13% 17.28B
-1.94%-6.36%-7.05%+516.16% 14.46B
-2.28%-5.09%+48.86%+153.82% 14.23B
Average -0.91%-3.96%+32.85%+152.38% 30.3B
Weighted average by Cap. -0.86%-3.80%+30.45%+123.67%

Financials

2026 *2027 *
Net sales 1.81B 2.09B 1.71B 1.55B 2.91B 200B 2.92B 20.31B 7.81B 102B 7.87B 7.69B 322B 1.81B 2.1B 1.72B 1.55B 2.92B 201B 2.93B 20.39B 7.84B 102B 7.9B 7.72B 323B
Net income -1.38B -1.6B -1.3B -1.18B -2.22B -153B -2.23B -15.49B -5.95B -77.58B -6B -5.87B -245B -1.31B -1.52B -1.24B -1.12B -2.1B -145B -2.12B -14.71B -5.66B -73.68B -5.7B -5.57B -233B
Net Debt -11.37B -13.18B -10.76B -9.75B -18.29B -1,260B -18.38B -128B -49.13B -640B -49.52B -48.42B -2,025B -10.03B -11.63B -9.5B -8.6B -16.13B -1,112B -16.22B -113B -43.35B -565B -43.69B -42.72B -1,787B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
-
Date Price Change
26-09-11 €83.55 +0.66%
26-09-10 €83.00 -1.66%
26-09-09 €84.40 -1.00%
26-09-08 €85.25 -4.96%
26-09-07 €89.70 +0.50%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
82.90EUR
Average target price
102.47EUR
Spread / Average Target
+23.60%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!